Status:
UNKNOWN
GTP Regimen in the Treatment of Refractory/Recurrent HLH
Lead Sponsor:
Beijing Friendship Hospital
Conditions:
Refractory
Recurrence
Eligibility:
All Genders
1+ years
Phase:
PHASE3
Brief Summary
The goal of this clinical trial is to learn about efficacy and safety of GTP regimen in refractory/recurrent hemophagocytic lymphohistiocytosis. The main questions it aims to answer are: * Overall re...
Detailed Description
Refractory/recurrent hemophagocytic lymphohistiocytosis will be treated with emapalumab combined with teniposide and methylprednisolone. Observed the overall response rate and side effects.
Eligibility Criteria
Inclusion
- Male and female patients ≥1 month of age with HLH
- Definitive diagnosis of HLH: meets the molecular diagnosis of pHLH or has a family history of HLH, or meets at least 5 of the 8 diagnostic criteria of HLH-2004.
- The investigators assessed the presence of refractory/recurrent HLH disease. Patients must meet one of the following criteria assessed by the investigator:
- Previous conventional HLH treatment did not respond.
- The patients were not satisfied with the efficacy of conventional HLH treatment or their condition worsened.
- HLH reactivation occurs. Reactivation is defined as: worsening of two or more HLH clinical and laboratory criteria (after initial remission).
- According to the researchers, the expected survival was more than 2 weeks.
- The informed consent is signed by the patient or his legal guardian (patients under 18 years), or by the patient's legally authorized representative.
- Women who are fertile are willing to use a highly effective contraceptive method from the start of the study until 6 months after the end of the last course of treatment.
Exclusion
- There is active mycobacterium, histoplasma capsulatus, Salmonella, or leishmania infection.
- There is uncontrolled active gastrointestinal bleeding.
- The investigator believes that there are any serious comorbidities or any other conditions that make the patient unsuitable for treatment.
- A history of hypersensitivity or hypersensitivity to any component of the drug in the study protocol, such as polysorbate.
- Had received the BCG vaccine within 12 weeks prior to screening.
- Have received live or attenuated vaccine (except BCG) within 4 weeks prior to screening.
- Pregnancy patients.
- Within 4 weeks prior to enrollment in this study, another concurrent clinical intervention study was enrolled.
- There is any condition or circumstance that the investigator believes may cause the patient to be unable to complete the study or to comply with study procedures or requirements.
Key Trial Info
Start Date :
September 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2025
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06038422
Start Date
September 15 2023
End Date
September 15 2025
Last Update
September 14 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.